Categories: Wire Stories

Five of Kirin�s Proprietary Lactococcus lactis strain Plasma Products Registered as �Foods with Function Claims�

– First-ever Immune System Support Foods to Become Available in Japan –

TOKYO–(BUSINESS WIRE)–Kirin Holdings Company, Limited (TOKYO:2503) announced today that five of its products*1 that utilize Lactococcus lactis strain Plasma were registered as Foods with Function Claims with Japan’s Consumer Affairs Agency (CAA). This is the first time that an immune system-related product has been registered in Japan. When registration is accepted by the CAA, labeling of “function claims” (usually health benefits) on products becomes possible. This registration provides the value of reliability and reassurance for consumers when choosing products.

*1: Three soft drinks and two supplements, to be announced at a later date.


The Kirin Group Vision 2027 sets out the broad goal of creating value across the world of food & beverages to pharmaceuticals and becoming a global leader in CSV*2. To augment the Group’s existing Food & Beverages domain and Pharmaceuticals domain, the Group has launched a new Health Science domain to help people stay fit and healthy by leveraging advanced fermentation and biotechnology the Group has amassed over the years. One example of this is leveraging the Group’s 35 years of research that led to the development of Lactococcus lactis strain Plasma, jointly developed across Group companies. Moving forward, Kirin Group will accelerate domestic sales as well as expand overseas sales of products that utilize Lactococcus lactis strain Plasma, leading to further contribution to the health and well-being of the global community.

*2: Creating Shared Value. Combined added value for consumers as well as for society at large.

Kirin’s proprietary Lactococcus lactis strain Plasma

The Lactococcus lactis strain Plasma is a type strain of Lactococcus lactis, which is a natural lactic acid bacterium mainly used for the fermentation of cheese and yogurt. The Lactococcus lactis strain Plasma is a product of joint research by Kirin Holdings, Koiwai Dairy Products, and Kyowa Hakko Bio, and a number of relevant papers have been published and many presentations have been given at medical societies in cooperation with medical schools and research institutions.

Summary of the Functional Food Labeling Registration to the CAA

This product contains Lactococcus lactis strain Plasma. It has been shown to support maintenance of the immune system in healthy individuals by stimulating pDC (plasmacytoid dendritic cells).

[Functional Ingredient]

Lactococcus lactis strain Plasma (100billion/day)

Container and Packaging Label Information

  1. “Supports maintenance of the immune system in healthy individuals” (excerpt from the above registration summary)
  2. “World’s first* lactic acid bacterium that stimulates pDC”

    *: World’s first-ever published paper on the effects of Lactic acid bacterium on pDC

    (Based on published material medical periodicals’ websites and PubMed) 

Contacts

Press Contact

Corporate Communication Department

Kirin Holdings Company, Limited

Russell Roll

Nakano Central Park South, 4-10-2 Nakano, Nakano-ku, Tokyo

Tel +81-3-6837-7028

email address: Russell_Roll@kirin.co.jp
Kirin Holdings Homepage: www.kirinholdings.co.jp/english/

Alex

Recent Posts

Zhengzhou: Interactive Exhibitions on the International Museum Day

ZHENGZHOU, China--(BUSINESS WIRE)--In central China’s Zhengzhou city, visiting museums has become a new trend of…

4 hours ago

Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally

Mollie Pearce, star of the UK reality TV show ‘The Traitors’ who was diagnosed with…

14 hours ago

Quality Building Award 2024 Unveils Finalist List

QBA 2024 Announces 35 Finalists Competing for Hong Kong's Highest Honour in the Building Industry…

2 days ago

UXLINK Tops RootData’s Latest X Hot Items List and DappRadar Social Apps List

SINGAPORE - Media OutReach Newswire - 17 May 2024 - UXLINK, the Web3 social platform…

2 days ago

Australia Construction Industry Report 2024: Growth to Slow to 2% in Real-terms this Year Following 9% Growth in 2023 – Forecasts to 2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Australia Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to…

2 days ago

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

Three-part podcast interview features The mechanism of action of ANKTIVA® activating NK cells, Killer T…

2 days ago